Avastin vs. Lucentis
A press release just issued by the National Eye Institute states that a “NIH study finds Avastin and Lucentis are equally effective in treating age-related macular degeneration.” The CATT (Comparison of AMD Treatments Trials) study began in 2008 and now reports the results for 1,185 patients treated at 43 clinical centers in the United States. Patients received Lucentis monthly or PRN, or Avastin monthly or PRN. So far, visual acuity improvement was virtually identical for either drug when given monthly, and no difference was found in the percentage of patients who had gains or losses in vision. There was virtually no difference between results when patients received the drugfs on a PRN dosing schedule vs. on a monthly regimen.
The percentage of patients experiencing adverse effects, that may or may not be connected with the drug treatment, were similar for both drugs (24% rate for Avastin, 19% rate for Lucentis). Investigators will continue studying patients through a second year of treatment to procure information on longer term effects of both drugs.